GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aurinia Pharmaceuticals Inc (FRA:IKAP) » Definitions » Cash Flow for Dividends

Aurinia Pharmaceuticals (FRA:IKAP) Cash Flow for Dividends : €0.0 Mil (TTM As of Dec. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Aurinia Pharmaceuticals Cash Flow for Dividends?

Aurinia Pharmaceuticals's cash flow for dividends for the three months ended in Dec. 2024 was €0.0 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Dec. 2024 was €0.0 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Aurinia Pharmaceuticals Cash Flow for Dividends Historical Data

The historical data trend for Aurinia Pharmaceuticals's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurinia Pharmaceuticals Cash Flow for Dividends Chart

Aurinia Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Aurinia Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Aurinia Pharmaceuticals Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aurinia Pharmaceuticals Cash Flow for Dividends Related Terms

Thank you for viewing the detailed overview of Aurinia Pharmaceuticals's Cash Flow for Dividends provided by GuruFocus.com. Please click on the following links to see related term pages.

Aurinia Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aurinia Pharmaceuticals Inc (FRA:IKAP) » Definitions » Cash Flow for Dividends
Comparable Companies
INVA ADPT SNDX NVAX MDXG IOVA ARDX VRDN ETNB SYRE VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
AUPH:USA
Address
14315 - 118 Avenue, Suite 140, Edmonton, AB, CAN, T5L 4S6
Website
https://www.auriniapharma.com
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Aurinia Pharmaceuticals Headlines

No Headlines